GPT and Cirrhosis: In contrast, Bril et al. suggest liver enzymes may remain the main diagnostic biomarker of advanced fibrosis in patients with T2DM due to their availability and high accuracy in excluding advanced cirrhosis, particularly in comparison with more costly and more complicated diagnostic options that turn out to perform equally well as AST/ALT levels in this population [28].